跳至主要内容
临床试验/NCT07430722
NCT07430722已完成不适用

A Cross-sectional Study of Serum Vitamin B6 Levels in People Living With Parkinson's Disease

University of Rochester1 个研究点 分布在 1 个国家目标入组 288 人开始时间: 2024年7月1日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
288
试验地点
1
主要终点
Serum levels of vitamin B6 (Fasting)

研究概览

简要总结

The purpose of this study is to estimate the prevalence of abnormal serum levels of vitamin B6, and the associations of those levels with demographic and clinical variables in a randomly selected sample of people living with Parkinson's disease, compared to historical controls.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • People with a clinical diagnosis of Parkinson's disease according to the diagnostic criteria of the Movement Disorders Society [Postuma 2015].
  • Participants are ≥ 18 years old.
  • As determined by the study investigators, participants are able to communicate at a level sufficient to undergo study interviews.
  • As determined by the study investigators, participants have the capacity to provide written informed consent and the ability to comply with all study procedures.

排除标准

  • People expected to have abnormal vitamin B6 levels due to underlying conditions (renal disease, bowel disease, rheumatoid arthritis).
  • People taking medications (other than levodopa) expected to interfere with B6 levels (steroids, cycloserine, hydralazine, isoniazid, theophylline, penicillamine).

研究组 & 干预措施

Historical controls

144 matched controls from the National Health and Nutrition Examination Survey (NHANES)

People living with Parkinson's disease

144 people living with Parkinson's disease randomly selected from a Movement Disorders Clinic in Rochester, NY, USA

结局指标

主要结局

Serum levels of vitamin B6 (Fasting)

时间窗: At enrollment

nmol/L (log-transformed)

次要结局

  • Ethnicity(At enrollment)
  • Body mass index(At enrollment)
  • Diabetes(At enrollment)
  • Smoking(At enrollment)
  • Alcohol use(At enrollment)
  • Daily consumption of protein in the last 30 days(At enrollment)
  • Daily consumption of food rich in B6 in the last 30 days(At enrollment)
  • Food insecurity(At enrollment)
  • Vitamin B6 supplement use in the last 30 days(At enrollment)
  • Vitamin supplement use in the last 30 days(At enrollment)
  • History of oral contraceptive pill use(At enrollment)
  • Age at onset of Parkinson's disease(At enrollment)
  • Disease duration(At enrollment)
  • Disease stage(At enrollment)
  • Disease severity(At enrollment)
  • Levodopa dosage(At enrollment)
  • Dosage of dopa decarboxylase inhibitor(At enrollment)
  • Levodopa/Carbidopa ratio(At enrollment)
  • Cathecol-o-methyl-transferase inhibitor use(At enrollment)
  • Dosage of cathecol-o-methyl-transferase inhibitor(At enrollment)
  • Levodopa equivalent daily dosage(At enrollment)
  • Polyneuropathy(At enrollment)
  • Epilepsy(At enrollment)
  • Serum levels of vitamin B12 (Fasting)(At enrollment)
  • Serum levels of homocysteine (Fasting)(At enrollment)
  • Serum levels of methylmalonic acid (Fasting)(At enrollment)
  • Serum levels of folic acid (Fasting)(At enrollment)
  • Age(At enrollment)
  • Sex(At enrollment)
  • Race(At enrollment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karlo Lizarraga

Associate Professor of Neurology

University of Rochester

研究点 (1)

Loading locations...

相似试验